Tempus AI CFO James Rogers sells $59,057 in inventory

CHICAGO—James William Rogers (NYSE:ROG), Chief Monetary Officer of Tempus AI, Inc. (NASDAQ:TEM), just lately bought shares of the corporate’s Class A standard inventory amid a difficult week for the corporate’s inventory, which has declined over 7%. In keeping with a submitting with the Securities and Change Fee, Rogers bought 1,468 shares on December 16, totaling roughly $59,057. The shares had been bought at a weighted common worth of $40.23, with transactions occurring at costs starting from $40.00 to $40.56. Based mostly on InvestingPro evaluation, the inventory is at the moment buying and selling close to its Honest Worth.

The transaction was a “promote to cowl” sale, mandated by Tempus AI’s fairness incentive plans to satisfy statutory tax withholding obligations associated to the vesting of restricted inventory items. This sale was not a discretionary determination by Rogers. Following this transaction, Rogers retains possession of 229,812 shares of Tempus AI. InvestingPro knowledge reveals the corporate maintains robust liquidity with a present ratio of two.69, indicating wholesome short-term monetary stability. InvestingPro subscribers have entry to eight extra key insights about Tempus AI’s monetary place and market efficiency.

In different current information, Tempus AI’s monetary efficiency and strategic acquisitions have attracted vital consideration from monetary analysts. The corporate’s current earnings report led Piper Sandler to boost its worth goal from $40 to $70, whereas sustaining a impartial ranking. Equally, Stifel downgraded Tempus AI from Purchase to Maintain however elevated the value goal to $65, reflecting the current acquisition of Ambry Genetics.

Needham additionally raised its inventory worth goal for Tempus AI to $56 following the corporate’s third-quarter outcomes and the Ambry Genetics acquisition. In the meantime, Tempus AI has partnered with Avacta Therapeutics to make the most of AI for oncology drug growth. One other notable growth contains FDA clearance for Tempus AI’s Tempus ECG-AF gadget, which makes use of AI to determine sufferers at larger threat of atrial fibrillation/flutter.

These current developments have led to varied monetary corporations adjusting their inventory worth targets for Tempus AI. Whereas Piper Sandler and Stifel stay cautious with a Impartial and Maintain ranking respectively, Needham maintains its Purchase ranking, reflecting optimistic expectations for the corporate’s development trajectory. It is very important word that these rankings and targets are based mostly on the corporate’s current monetary efficiency and strategic strikes, and never on the longer term inventory worth actions.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.